Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity

Conclusion:
Patients with morbid obesity required less than the recommended 1 mg/kg enoxaparin dose to achieve therapeutic peak anti-Xa levels; therefore, initiation with lower dosages is prudent and anti-Xa monitoring should guide dosage adjustments.

Source: Clinical and Applied Thrombosis/Hemostasis - July 24, 2015 Category: Hematology Authors: Thompson-Moore, N. R., Wanat, M. A., Putney, D. R., Liebl, P. H. N., Chandler, W. L., Muntz, J. E. Tags: Original Articles Source Type: research